Health
FDA requires GLP-1 drugs to warn about potential vision loss risk.
NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.
OriginalSourceNew York PostUnited StatesLeanCenter-rightCredibilityPublished20:51 UTCRatings: AllSides, MBFCSourceNew York PostUnited StatesLeanCenter-rightCredibilityPublished20:51 UTCRatings: AllSides, MBFC
“GLP-1 drugs must have new warning label over incurable blindness condition, says FDA”
FDA warns GLP-1 drugs may raise risk of NAION eye condition
Key points
- FDA warns GLP-1 drugs may increase risk of nonarteritic anterior ischemic optic neuropathy.
- Agency orders safety label updates for Ozempic, Wegovy, Zepbound, Mounjaro and others.
- NAION can cause permanent vision loss with limited or no cure.
- Study suggests fourfold increased NAION risk among diabetes patients using semaglutide.
- Healthcare providers told to monitor symptoms and refer to ophthalmology if NAION suspected.
Other reports
- SourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STATSourceSTATUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at STAT
“STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition”
- SourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityRatings: AllSides, MBFCRead at MarketWatchSourceMarketWatchUnited StatesOwner: Dow Jones & CompanyLeanCenterCredibilityRatings: AllSides, MBFCRead at MarketWatch
“Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss”
- SourceQuartzUnited StatesLeanUnratedCredibilityUnratedRead at QuartzSourceQuartzUnited StatesLeanUnratedCredibilityUnratedRead at Quartz
“FDA is requiring weight loss drug makers to add a vision loss warning”
- SourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The IndependentSourceThe IndependentUnited KingdomLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Independent
- SourceAP NewsUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at AP NewsSourceAP NewsUnited StatesLeanCenterCredibilityRatings: AllSides, MBFCRead at AP News
- SourceThe Washington PostUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Washington PostSourceThe Washington PostUnited StatesLeanCenter-leftCredibilityRatings: AllSides, MBFCRead at The Washington Post
“FDA tells GLP-1 makers to warn of potential vision loss side effect”
- SourceGizmodoUnited StatesLeanUnratedCredibilityUnratedRead at GizmodoSourceGizmodoUnited StatesLeanUnratedCredibilityUnratedRead at Gizmodo
“FDA Orders New Vision Loss Warning for Ozempic and Other GLP-1s”
- SourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS NewsSourceCBS NewsUnited StatesLeanUnratedCredibilityUnratedRead at CBS News
“FDA warns of rare vision-loss side effect from GLP-1 drugs”
How it got here
New York Post publishes the article.
concise.news reads it.
Grouped with 8 other reports as story 9.
The Brief ranks it 9th.
9 9 FDA requires GLP-1 drugs to warn about potential vision loss risk.
NAION is an eye stroke that can cause sudden, permanent vision loss and has no proven treatment.